A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macular Edema

Trial Profile

A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macular Edema

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2016

At a glance

  • Drugs Dexamethasone (Primary) ; Ranibizumab
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 02 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jun 2013 New source identified and integrated (United Kingdom Clinical Research Network, 12137).
    • 03 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top